Unveiling the signaling network of FLT3-ITD AML improves drug sensitivity prediction

Unveiling the signaling network of FLT3-ITD AML improves drug sensitivity prediction

Currently, the identification of patient-specific therapies in cancer is mainly informed by personalized genomic analysis. In the setting of acute myeloid leukemia (AML), patient-drug treatment matching fails in a subset of patients harboring atypical internal tandem duplications (ITDs) in the tyros...

Full description

Bibliographic Details
Main Authors: Sara Latini, Veronica Venafra, Giorgia Massacci, Valeria Bica, Simone Graziosi, Giusj Monia Pugliese, Marta Iannuccelli, Filippo Frioni, Gessica Minnella, John Donald Marra, Patrizia Chiusolo, Gerardo Pepe, Manuela Helmer Citterich, Dimitros Mougiakakos, Martin Böttcher, Thomas Fischer, Livia Perfetto, Francesca Sacco
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2024-04-01
Series:eLife
Subjects:
mouse
acute myeloid leukemia
tyrosine kinase
Boolean model
drug resistance
cancer therapy
Online Access:https://elifesciences.org/articles/90532

Internet

https://elifesciences.org/articles/90532

Similar Items